• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Biophan Makes Available New Online Video Describing Breakthrough MYO-VAD(TM) Cardiac Assist Device; Duke University Surgeon Describes How Unique Device Kept Patient Alive Through Episode of Acute Heart Failure

Posted on: Thursday, 15 September 2005, 18:00 CDT

Biophan Technologies, Inc. (OTCBB: BIPH) a developer of next-generation biomedical technology, announced today the online availability of a streaming-video presentation, the second in a three-part series, that focuses on a proprietary breakthrough cardiac assist device Biophan will be developing with advanced biomedical technology partner MYOTECH, LLC.

Biophan recently executed a Letter of Intent that includes plans to acquire marketing rights to MYOTECH's breakthrough cardiac assist device, called the MYO-VAD(TM). It is designed to assist the best blood pump known to man - the heart - to maintain healthy blood flow during heart failure, while eliminating most of the serious complications associated with currently available cardiac assist devices. The MYO-VAD(TM) is the first in a family of products based upon Direct Mechanical Ventricular Actuation (DMVA) technology.

This video focuses on how doctors at Duke University Medical Center used the technology to save the life a young woman who was rushed to the hospital during an episode of heart failure caused by a viral infection. In the video, Duke surgeon and professor, Dr. James E. Lowe, describes how his team restored blood flow in the woman in a matter of just three or four minutes, which kept her heart beating, saving her life.

Biophan recently announced a key strategic business initiative to enter the fast-growing market for cardiac assist devices, estimated by industry observers to have a potential of $28 billion worldwide. Following the closing of the transaction with MYOTECH, Biophan will oversee the development and regulatory approval of the MYO-VAD cardiac assist technology, as well as all future MYOTECH development programs. In addition, at closing Biophan will acquire a substantial minority interest with the right to acquire a controlling interest in MYOTECH.

Some leading medical device companies have already expressed initial interest in the MYO-VAD(TM) device. The simple device is less invasive than other cardiac assist devices on the market and therefore is expected to be safer and more affordable. Previous versions of DMVA technology have been implanted experimentally in 700 animals with impressive results in five patients. Human lives were saved.

To view the video online, please visit http://www.tril01.com/biophan/myovad.html.

About MYOTECH, LLC

MYOTECH, LLC, is a privately-held medical technology development company, formed in 2003 to commercialize a family of medical products based upon Direct Mechanical Ventricular Actuation ("DMVA") cardiac assist technology. This technology has permitted the development of minimally invasive heart assist devices that promise to provide safer, more effective, and more affordable treatment for more patients with many types of heart failure. MYOTECH has relationships with leading physicians and medical institutions. They have assisted MYOTECH in both research and planning. MYOTECH has several pending patents pertaining to the DMVA technology.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to be safely and effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 144 U.S. patents, licenses, or applications. This total includes 41 issued U.S. patents, 9 recently-allowed applications that will issue as patents in the near future, and 94 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific (NYSE: BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Source: Business Wire

More News in this Category